The Division of Hematology/Oncology is actively advancing the understanding, diagnosis, and treatment of cancer and hematological disorders through nationally-recognized basic, translational, clinical, and population-based research programs. The Division has enjoyed a long history of outstanding research support, with $26 million in total research funding in FY 2019 and $11.7 million in peer-reviewed direct funding. The UPMC Hillman Cancer Center serves as the hub for the Hematology/Oncology scientific and clinical research activities in cancer. UPMC Hillman is Western Pennsylvania’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and is ranked 12th in NCI funding.
Through our clinical research programs, our faculty are defining lifesaving approaches and accelerating the transformation of breakthroughs in their laboratories into clinical application for patients within the region and beyond. Clinical faculty are actively enrolling patients into clinical trials that investigate novel agents and combination regimens. In 2018-19, Division faculty enrolled 1,231 patients into various therapeutic, non-therapeutic, and compassionate-use clinical trials.
Within the Division, several members are internationally recognized for their leadership and expertise in various sold tumors. With the patient at the center of its mission, Division faculty strive to improve their understanding of the biological basis of cancer to develop new approaches for the prevention of cancer and to refine and redefine the ways in which patients are diagnosed and treated.
Benign Hematology Research
The Division includes a Section of Benign Hematology with more than 10 physician-scientists and research investigators, and is of the largest benign hematology programs in the U.S. Areas of excellence include hemophilia and bleeding disorders, and sickle cell disease The section oversees more than 20 clinical studies, primarily in sickle cell disease, but with a growing number of trials in other areas of benign hematology, such as acquired platelet disorders and autoimmune hemolytic anemias.
Division of Hematology/Oncology
UPMC Cancer Pavilion
5150 Centre Avenue, 5th floor
Pittsburgh, PA 15232
412-648-6575 | Email Us
UPMC Hillman Cancer Center
5115 Centre Avenue
Pittsburgh, PA 15232